Ticker AKTX – Akari Therapeutics – sales, description, marketcap – Tickerday.com

AKTX

Akari Therapeutics

–

Index: NASDAQ; Sector: Healthcare; Industry: Biotechnology & Drugs;

Marketcap: 56.89M; Volume: 40.62K; AvgVol 3m: 258.97K; Beta: 1.40;

Cost estimate:

P/E: –; EPS: -0.91; EPS growth quarter/prev quarter: -8.20%;

EPS growth this year: 12.60%; EPS growth past 5 years: 16.30%;

EPS ttm: -0.91;

P/S: ; P/B: 16.82; P/Cashflow: 4.99; P/FCF: ;

Sales: –; Sales growth quarter/prev quarter: ; Sales growth past 5 years: ;

Profitability:

Gross Margin: ; Profit Margin: ; Operating Margin: ;

ROA – return on assets: -211.40%; ROE – return on equity: ; LT Debt/Equity: 0.00; Total Debt/Equity: 0.00;

Dividend: –; Dividend Yield (%): –;

Insider Ownership: 41.85%; Insider Transactions:0.00%;

Institutional Ownership: 4.60%; Institutional Transactions: 82.11%;

Data update: 07.10.2020.